Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
faldaprevir + raltegravir
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Faldaprevir + raltegravir is a combination of two small molecule antivirals used together in clinical contexts, primarily in the management of patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Faldaprevir is a potent inhibitor of the HCV NS3/4A protease and also inhibits UDP-glucuronosyltransferase 1A1 (UGT1A1), which can impact the pharmacokinetics of other drugs. Raltegravir is an HIV-1 integrase strand transfer inhibitor used as part of antiretroviral therapy. The combination has primarily been studied for drug-drug interactions and safety in co-infected patients.
- Other names
- faldaprevir + raltegravir
02
Targets
UGT1A1 (UDP-glucuronosyltransferase 1A1)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on faldaprevir + raltegravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on faldaprevir + raltegravir.